This post was originally published on this site
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.
The pharmaceutical company said Enhertu has been recommended by the EU’s Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
